Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
# x% [' k; C6 K+ S: P/ M; [
# Z' Z5 ]8 b) m8 {# {; a! H
/ @8 d; E% U& C- P& y. ?$ K( \3 oSub-category:' M' N: L! \ P! f" x
Molecular Targets
7 o; \+ I; Q* O; d1 Y. ]' Q4 r* J( D- Y: l% |$ z
' n) }# l; j: x% q8 g
Category:
9 s# C( m+ m4 n* j7 S2 n n( WTumor Biology ; H# n/ V( W8 @
4 O( N2 s) r5 n
& p+ C4 Q) r6 }% `- X0 BMeeting:8 X, H# A( _" E4 z4 o
2011 ASCO Annual Meeting 6 o3 G# M6 ^8 X& Z
6 M- \# G- e' E! l3 q% g3 q
2 l1 U: j+ V2 P
Session Type and Session Title:; k7 N1 \' Z/ O$ Z# Y
Poster Discussion Session, Tumor Biology
! A8 l6 j" w( [2 J, i: p0 }
' ?8 p; j! H$ X0 K% ]7 M5 j
8 ~& i" f1 @+ {* {Abstract No:. ]: q6 c0 ^# n2 c
10517
- U& R0 ?- A4 _# s* r U6 W7 k/ M6 K
. B+ T! H- o! T0 |
Citation:
8 U- }0 @9 Q% L. b3 A! |J Clin Oncol 29: 2011 (suppl; abstr 10517) ; o$ }2 N4 F+ q$ X9 E. e
/ x( v' E- ? z9 O
) t, Z1 F0 s# b6 B) G7 D# vAuthor(s):
7 ]" U& i6 z2 I9 C: t& p! z0 rJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
$ I* }0 R& T' _0 q$ O* a2 C2 c1 B+ q- H
+ [) ]6 l0 V7 p* p9 S# o- z5 B! a
7 ]: ~2 n4 r- s8 \7 HAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
: D0 M; T F2 Z2 L# w9 `) H4 R8 S, P/ V6 e V0 w s" G( J! w
Abstract Disclosures
# N0 j# |/ l- |& B4 t2 x3 X& L( U
Abstract:
5 Y; n- J3 J) S7 C. @. s2 D$ l
: [ j7 d* N- |$ H+ c/ b; V# r; t7 b' w& T# N( Q/ O5 A
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
6 {- H6 C8 h# l& D* q( G; |- u8 g- |. D6 }
# O4 \# ^/ j' p: ]6 D) Z" o |
7 N- u# `7 O1 m' H4 s) \ S. w
显身卡
